Bonharen IVN 10mg/10ml 5 x 6ml

Item No.90560
Bonharen IV 60mg for treatment of joint disease associated with non-infectious synovitis. Bonharen gives systemic intravenous treatment. Joint disease affects not only the articular cartilage, but also the surrounding soft tissues and vascular system. The main protective anti-inflammatory effect of

Description

Bonharen IV 60mg for treatment of joint disease associated with non-infectious synovitis. Bonharen gives systemic intravenous treatment. Joint disease affects not only the articular cartilage, but also the surrounding soft tissues and vascular system. The main protective anti-inflammatory effect of IVN administration of sodium hyaluronate is achieved through formation of the protective glycocalyx coating on the lumen of blood vessels. The glycocalyx prevents vascular leakage and reduces penetration of inflammatory me-diators into the surrounding tissue of the joint. The interaction of exogenous intravenously applied HA has been described as protection against inflammatory stimuli like LPS (bacterial endotoxin).

Treatment consists of one vial of 6ml per week for 5 weeks. Bonharen IVN legal category is VPO.For more info contact your Interchem territory manager.

Specifications

Species
Equine
Business Unit
EQU
Legal catagory
VPO
Active/Ingredient(s)
Sodium Hyaluronate

Bonharen IVN 10mg/10ml 5 x 6ml

Item No.90560
Bonharen IV 60mg for treatment of joint disease associated with non-infectious synovitis. Bonharen gives systemic intravenous treatment. Joint disease affects not only the articular cartilage, but also the surrounding soft tissues and vascular system. The main protective anti-inflammatory effect of

Description

Bonharen IV 60mg for treatment of joint disease associated with non-infectious synovitis. Bonharen gives systemic intravenous treatment. Joint disease affects not only the articular cartilage, but also the surrounding soft tissues and vascular system. The main protective anti-inflammatory effect of IVN administration of sodium hyaluronate is achieved through formation of the protective glycocalyx coating on the lumen of blood vessels. The glycocalyx prevents vascular leakage and reduces penetration of inflammatory me-diators into the surrounding tissue of the joint. The interaction of exogenous intravenously applied HA has been described as protection against inflammatory stimuli like LPS (bacterial endotoxin).

Treatment consists of one vial of 6ml per week for 5 weeks. Bonharen IVN legal category is VPO.For more info contact your Interchem territory manager.

Specifications

Species
Equine
Business Unit
EQU
Legal catagory
VPO
Active/Ingredient(s)
Sodium Hyaluronate

T: +353 (0)1 451 8959     F: +353 (0)1 4512540
info@interchem.ie

Interchem (Ireland) Ltd. Unit 29, Cookstown Industrial Estate, Dublin 24, D24 V9FP.

© Copyright 2024 VetHub from Interchem. All rights reserved. Powered by Sana Commerce.